The Artima Developer Community
Sponsored Link

Java Buzz Forum
Keryx announces positive interim results for mid stage trial drug for diabetic nephropathy treatment

0 replies on 1 page.

Welcome Guest
  Sign In

Go back to the topic listing  Back to Topic List Click to reply to this topic  Reply to this Topic Click to search messages in this forum  Search Forum Click for a threaded view of the topic  Threaded View   
Previous Topic   Next Topic
Flat View: This topic has 0 replies on 1 page
Angsuman Chakraborty

Posts: 19816
Nickname: angsuman
Registered: Dec, 2003

Angsuman Chakraborty is the CEO and Chief Architect at Taragana
Keryx announces positive interim results for mid stage trial drug for diabetic nephropathy treatment Posted: May 7, 2005 11:27 AM
Reply to this message Reply

This post originated from an RSS feed registered with Java Buzz by Angsuman Chakraborty.
Original Post: Keryx announces positive interim results for mid stage trial drug for diabetic nephropathy treatment
Feed Title: Simple Thoughts on Java
Feed URL: http://sedoparking.com/search/registrar.php?domain=®istrar=sedopark
Feed Description: News and views as a Software Architect and Entepreneur on Java and related Technologies.
Latest Java Buzz Posts
Latest Java Buzz Posts by Angsuman Chakraborty
Latest Posts From Simple Thoughts on Java

Advertisement
Keryx Biopharmaceuticals (KERX) Announces Positive Interim Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For Treatment Of Diabetic Nephropathy. Around 40% of diabetic patients progress to diabetic nephropathy. So far the progression can be delayed by tight blood sugar control etc. However there is no known cure. In the Phase II study, 24 percent of [...]

Read: Keryx announces positive interim results for mid stage trial drug for diabetic nephropathy treatment

Topic: Log4j 1.2.10 is out with Simple Logging Facade for Java (SLF4J) support Previous Topic   Next Topic Topic: Using Java 1.5 on OS X 10.4

Sponsored Links



Google
  Web Artima.com   

Copyright © 1996-2019 Artima, Inc. All Rights Reserved. - Privacy Policy - Terms of Use